Previous 10 | Next 10 |
LEXINGTON, Mass. , March 12, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers provided a corporate update and reported financial results for the fourth quarter and full yea...
3 Penny Stocks Turning Heads This Week When it comes to stocks trading under $5, or penny stocks , you really need to have a good handle on your personal risk tolerance. I’m not talking about how you play the lottery and handle yourself at a slot machine. I’m talking about inves...
LEXINGTON, Mass. , March 10, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, announced the triggering of a $15.1M milestone payment from HealthCare Royalty Partners (HC...
The severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2 for short, has definitely made its presence felt on Wall Street during the opening weeks of 2020. Despite a strong start to 2020, the Dow Jones Industrial Average , the Nasdaq Composite , and the S&P 5...
Agenus ( AGEN ) is a pharmaceutical company that has long studied the immune system and worked to create therapies for infectious diseases and cancers. Its QS-21 Stimulon is one of the ingredients in GSK's Shingrix vaccine, which has been a big success. The main future value of Agenus, howev...
Shares of Agenus (NASDAQ: AGEN) fell as much as 14.1% today after an update from the pipeline underwhelmed investors. The development-stage biopharmaceutical company announced positive interim data from a combination therapy of balstilimab (AGEN2034) and zalifrelimab (AGEN1884) as a second-l...
LEXINGTON, Mass. , Feb. 20, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, today announced new clinical data from pre-planned interim analyses of balstilimab (anti-PD-1)...
Shares of Agenus (NASDAQ: AGEN) rose as much as 12.1% today. While there wasn't any specific news lifting the stock, investors are anticipating good news ahead of the company's investor day, scheduled for tomorrow. The development-stage biopharmaceutical company is set to present clin...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Noteworthy events during the week of February 16 - 22 for healthcare investors. More news on: Agile Therapeutics, Inc., Merck & Co., Inc., Cellectar Biosciences, Inc., Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...